Home based objective measures of bradykinesia and dyskinesia will be important in managing Parkinsons Disease (PD). The Aim of this paper was to further validate the Parkinsons Kinetigraph system as a tool for measuring bradykinesia and dyskinesia by examining its capacity capture the effect of therapeutic interventions, detect bradykinesia and asymmetry in a newly diagnosed patients, and corre...

BACKGROUND In many patients with idiopathic Parkinson's disease, treatment with levodopa is complicated by fluctuations between an "off" period, when the medication is not working and the motor symptoms of parkinsonism are present, and an "on" period, when the medication is causing improved mobility, often accompanied by debilitating dyskinesias. In animal models of Parkinson's disease, there i...

This paper presents the design and methodology used to create a heterogeneous database for knowledge movement extraction in Parkinson’s Disease. This database is being constructed as part of REMPARK project and is composed of movement measurements acquired from inertial sensors, standard medical scales as Unified Parkinson’s Disease Rating Scale, and other information obtained from 90 Parkinson...

The CloudUPDRS app has been developed as a Class I medical device to assess the severity of motor symptoms for Parkinson’s Disease using a fully automated data capture and signal analysis process based on the standard Unified Parkinson’s Disease Rating Scale. In this paper we report on the design and development of the signal processing and longitudinal data analytics microservices developed to...

OBJECTIVE We sought to identify apathy metabolic bases in Parkinson disease (PD). METHODS A total of 45 patients with PD who were not clinically depressed (Montgomery-Åsberg Depression Rating Scale [MADRS] <21) and had no dementia (Mattis Dementia Rating Scale [MDRS] >130) were assessed with the Apathy Evaluation Scale (AES) and underwent a resting-state F-18 fluorodeoxyglucose PET (FDG-PET) ...

UNLABELLED Parkinson's disease (PD) is characterized by motor symptoms that cause the decline of functional capacity and affect the quality of life (QoL). OBJECTIVE To evaluate the impact of changes in balance and walking capacity on the PD. METHODS The instruments used were: Unified Parkinson's Disease Rating Scale (UPDRS), modified Hoehn and Yahr Scale (HY), Schwab and England scale (SE),...

Background Effects of dopaminergic medication on executive function in patients with Parkinson's disease (PD) are inconsistent. Objective We examined the effect of dopaminergic medication on executive function in 24 drug-naïve PD patients (de novo group) and in 21 PD patients on chronic dopaminergic medication (chronic medication group). Methods PD patients without dementia were included in...

BACKGROUND We previously reported gut dysbiosis in patients with Parkinson's disease (PD). OBJECTIVE The aim of this study is to examine whether gut dysbiosis correlates with the progression of PD. METHODS We examined changes in gut microbiota and demographic features in 2 years in 36 PD patients. RESULTS A change of total UPDRS scores in 2 years was predicted by the counts of Bifidobacte...

Parkinson's disease (PD) presents with extensive heterogeneity in symptomatology, inviting examination of disease subtypes. One significant categorization is by whether patients present at onset with tremor as the dominant symptom (TD) or with nontremor symptoms (NTD). We examined differences in quality of life between TD and NTD patients using the Parkinson's Disease Questionnaire-39 (PDQ-39),...